Haruo Miyata

1.5k total citations
81 papers, 1.0k citations indexed

About

Haruo Miyata is a scholar working on Spectroscopy, Organic Chemistry and Oncology. According to data from OpenAlex, Haruo Miyata has authored 81 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Spectroscopy, 19 papers in Organic Chemistry and 19 papers in Oncology. Recurrent topics in Haruo Miyata's work include Immunotherapy and Immune Responses (14 papers), Analytical Chemistry and Sensors (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Haruo Miyata is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Analytical Chemistry and Sensors (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Haruo Miyata collaborates with scholars based in Japan, United Kingdom and Nigeria. Haruo Miyata's co-authors include Kyoji Tôei, Yasuto Akiyama, Tadashi Ashizawa, Akira Iizuka, Yasuaki Shimoishi, Takashi Sugino, Ken Yamaguchi, Koichi Mitsuya, Yoko Nakasu and Nakamasa Hayashi and has published in prestigious journals such as Clinical Cancer Research, Biochemical and Biophysical Research Communications and Analytica Chimica Acta.

In The Last Decade

Haruo Miyata

75 papers receiving 967 citations

Peers

Haruo Miyata

ONCOL

IMMUN

SPECT

GENET

Siegfried Koch Germany

Yingru Zheng China

Michelle L. Turski United States

Ken-ichi Kiyomiya Japan

Kumiko Harada Japan

Vassiliki Theodorou Greece

Xueping Feng China

Koki Hasegawa Japan

Ewa Kurowska Poland

Siegfried Koch Germany

Haruo Miyata

217 ×0.6

ONCOL

68 ×0.2

IMMUN

482 ×1.6

39 ×0.3

SPECT

32 ×0.3

GENET

Citations per year, relative to Haruo Miyata Haruo Miyata (= 1×) peers Siegfried Koch

Countries citing papers authored by Haruo Miyata

Since Specialization

Citations

This map shows the geographic impact of Haruo Miyata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruo Miyata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruo Miyata more than expected).

Fields of papers citing papers by Haruo Miyata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruo Miyata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruo Miyata. The network helps show where Haruo Miyata may publish in the future.

Co-authorship network of co-authors of Haruo Miyata

This figure shows the co-authorship network connecting the top 25 collaborators of Haruo Miyata. A scholar is included among the top collaborators of Haruo Miyata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haruo Miyata. Haruo Miyata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ashizawa, Tadashi, Akira Iizuka, Takayuki Ando, et al.. (2024). In VivoAntitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models. In Vivo. 39(1). 80–95.

Deguchi, Shoichi, Yasuto Akiyama, Koichi Mitsuya, et al.. (2024). Genetic and Immunological Characterization of Brain Metastases from Solid Cancers. Anticancer Research. 44(5). 1983–1994. 1 indexed citations

Miyata, Haruo, Tadashi Ashizawa, Akira Iizuka, et al.. (2023). Localization ofEGFRMutations in Non-small-cell Lung Cancer Tissues Using Mutation-specific PNA-DNA Probes. Cancer Genomics & Proteomics. 20(4). 375–382. 1 indexed citations

Akiyama, Yasuto, Tadashi Ashizawa, Akira Iizuka, et al.. (2022). Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer Research. 42(11). 5233–5247. 4 indexed citations

Miyata, Haruo, Yasuto Akiyama, Akira Iizuka, et al.. (2021). Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software. Anticancer Research. 42(1). 419–427. 3 indexed citations

Mitsuya, Koichi, Yasuto Akiyama, Akira Iizuka, et al.. (2020). Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial. Anticancer Research. 40(11). 6473–6484. 30 indexed citations

Ashizawa, Tadashi, Akira Iizuka, Emiko Tanaka, et al.. (2019). Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunology Letters. 216. 43–50. 24 indexed citations

Akiyama, Yasuto, Tadashi Ashizawa, Akira Iizuka, et al.. (2017). The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunology Letters. 190. 20–25. 28 indexed citations

Miyata, Haruo, Tadashi Ashizawa, Akira Iizuka, et al.. (2017). Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. Cancer Genomics & Proteomics. 14(1). 83–92. 34 indexed citations

10.

Yoshikawa, Shusuke, Yoshio Kiyohara, Masaki Otsuka, et al.. (2017). Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. Anticancer Research. 37(3). 1321–1328. 6 indexed citations

11.

Ashizawa, Tadashi, Akira Iizuka, Ryota Kondou, et al.. (2016). Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clinical Cancer Research. 23(1). 149–158. 77 indexed citations

12.

Akiyama, Yasuto, Ryota Kondou, Haruo Miyata, et al.. (2016). Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. International Journal of Oncology. 49(3). 1099–1107. 18 indexed citations

13.

Akiyama, Yasuto, Tadashi Ashizawa, Masaru Komiyama, et al.. (2014). YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncology Reports. 32(1). 159–166. 33 indexed citations

14.

Akiyama, Yasuto, Masaru Komiyama, Haruo Miyata, et al.. (2014). Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. Oncology Reports. 31(4). 1683–1690. 23 indexed citations

15.

Ashizawa, Tadashi, Yasuto Akiyama, Haruo Miyata, et al.. (2014). Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line. International Journal of Oncology. 45(1). 411–418. 32 indexed citations

16.

Oshita, Chie, Akiko Kume, Haruo Miyata, et al.. (2012). Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncology Reports. 28(4). 1131–1138. 83 indexed citations

17.

Hayashi, Hideharu, et al.. (1993). Effects of phospholipase C on action potentials and intracellular Ca2+ concentration in guinea pig heart.. Japanese Circulation Journal. 57(4). 344–352. 5 indexed citations

18.

Kurata, Chinori, Kazuyuki Sakata, Takahisa Taguchi, et al.. (1990). SPECT Imaging with TI-201 and Ga-67 in Myocardial Sarcoidosis. Clinical Nuclear Medicine. 15(6). 408–411. 20 indexed citations

19.

Miyata, Haruo, Hideharu Hayashi, Shingo Suzuki, et al.. (1989). Dual loading of the fluorescent indicator fura-2 and 2,7-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF) in isolated myocytes. Biochemical and Biophysical Research Communications. 163(1). 500–505. 23 indexed citations

20.

Noda, Yasuko & Haruo Miyata. (1971). 1,1′-Dihydroxy-2,2′-azonaphthalene-4,4′-disulfonic Acid as a New Reagent for Magnesium. Bulletin of the Chemical Society of Japan. 44(8). 2291–2291. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact